Sumit K. Subudhi

Oncology

1220 Holcombe Blvd Fl 7
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 16, 2026

Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer.

Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer.

Journal: CA: a cancer journal for clinicians

Published: March 31, 2026

The path forward for T cell engagers in patients with prostate cancer.

The path forward for T cell engagers in patients with prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: February 09, 2026

Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy.

Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy.

Journal: JCO oncology practice

Published: November 07, 2025

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Journal: iScience

Published: September 04, 2025

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Journal: Nature communications

Published: July 25, 2025

Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer.

Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer.

Journal: Prostate cancer and prostatic diseases

Published: July 15, 2025

Safety, Efficacy, and Adjacent-level Fracture Risk Following Vertebral Augmentation and Radiofrequency Ablation for the Treatment of Spine Metastases in Patients with Cancer.

Safety, Efficacy, and Adjacent-level Fracture Risk Following Vertebral Augmentation and Radiofrequency Ablation for the Treatment of Spine Metastases in Patients with Cancer.

Journal: Radiology. Imaging cancer

Published: May 16, 2025

Neuropsychiatric events following high-dose steroid administration during early immune checkpoint therapy are more frequent with extended steroid exposure.

Neuropsychiatric events following high-dose steroid administration during early immune checkpoint therapy are more frequent with extended steroid exposure.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: May 11, 2025

Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.

Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.

Journal: European urology

Published: April 23, 2025

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 09, 2025

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 09, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026